"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.
about
Characterization of a novel angiogenic model based on stable, fluorescently labelled endothelial cell lines amenable to scale-up for high content screening.Role of placenta growth factor in cancer and inflammation.Epigenetic control of hypoxia inducible factor-1α-dependent expression of placental growth factor in hypoxic conditions.Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiationImmunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo.Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progressionA phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumoursNeovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone.Multiscale models of breast cancer progressionMacrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy.Overcoming resistance to antiangiogenic therapies.PlGF: a multitasking cytokine with disease-restricted activity.Assessing the in vivo efficacy of biologic antiangiogenic therapies.Placental growth factor in cancer.Signaling and molecular basis of bone marrow niche angiogenesis in leukemia.Placental growth factor: What hematologists need to know.Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.A novel synthetic derivative of human erythropoietin designed to bind to glycosaminoglycans.Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.Placental Growth Factor Triggers Epithelial-to-Mesenchymal Transition-like Changes in Rat Type II Alveolar Epithelial Cells: Activation of Nuclear Factor κB Signalling Pathway.Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment.
P2860
Q30531493-0D2801BE-09A6-482B-8DD3-E45E4557ED01Q33352793-DB5232D9-A756-462F-8616-904A8ADF437BQ34000432-EBF94955-3BAD-4DDF-8B06-A3C58EAADABBQ34052833-02B75731-F8EE-4369-A30E-567329626E57Q34855293-6D17AF65-0CCF-4F80-98CE-C3DB83BBD03DQ34947216-9C4ED13B-7B23-4863-B3C3-36E528EC2D47Q35115634-9258B048-0B92-4E50-9151-692BE928EB5EQ35147034-500DB8C7-8039-483E-9E85-3CC41010DE3CQ35879889-76A01C58-F8E5-4A01-A555-2E8DF4B268BDQ36047741-3110C55A-3DE2-47A4-A66D-C75E3E06FD1EQ36428702-0ED8269D-FBA1-49F7-AE75-1C584DC752DBQ36936900-B78C98E9-DB18-4DA9-851E-A11B28758649Q36990587-F71DBEE2-59E6-485F-B6C9-9521CDED7A97Q37404422-6B50B133-3BF9-4F82-B9FF-2A2BAB9FFE30Q37955105-34869190-B013-415F-9731-BE58C76A2008Q38002923-2206895B-07B1-4E37-8649-8EF11C9C8AADQ38024765-9732DC74-7D11-461B-AC03-B02D7D3BD98EQ38036234-B337D3FC-6E24-455D-A3EC-5D1C6684F93EQ38051013-E5EE84EA-403A-4139-8A24-47A586D2C05EQ38258289-C6057C6A-3BA6-4DC5-9CEC-A03A6AB10A0BQ38689750-1BB3FE0C-33C0-49D7-AC43-16B254690879Q38823169-9EEBC5F0-68DA-4EB6-B681-44DB41908D6AQ38942748-109F5F7E-F233-43DB-8399-C8FC1D6C14E5Q39008859-809CA367-713E-40B2-8D0E-79AC11D126F5Q39281709-0389D897-FEA8-488D-A421-75CCFEDB7375Q39340642-102EE748-323B-4FC0-9A20-DB408EE72ABCQ43580379-F217FECC-6A18-4607-B66A-CF7585171229Q46202577-1701DD1F-99C6-45BB-9421-4A59DAC0935CQ47218543-A4E3F5E1-F844-4252-B29E-7044AE4B2566Q53611300-A97ACE57-52BC-4272-A33E-EDBAE0D924E7Q55007680-8616B53C-2CA5-4FBF-BBBF-5B2A56A80C02
P2860
"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.
@en
"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.
@nl
type
label
"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.
@en
"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.
@nl
prefLabel
"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.
@en
"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.
@nl
P1476
"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF.
@en
P2093
Sonja Loges
Thomas Schmidt
P304
P356
10.1158/1078-0432.CCR-08-2276
P407
P577
2009-05-26T00:00:00Z